(YMAB) Y mAbs Therapeutics - Ratings and Ratios

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company that specializes in developing and commercializing innovative cancer treatments, including radioimmunotherapy and antibody-based therapeutics. The companys lead product, DANYELZA, is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor to treat pediatric patients with relapsed or refractory high-risk neuroblastoma. With a robust pipeline, Y-mAbs is also investigating DANYELZA for treating second-line relapsed osteosarcoma and has several other promising candidates in various stages of clinical trials, including GD2-SADA, Omburtamab, CD38-SADA, and GD2-GD3 Vaccine.

The companys proprietary SADA PRIT technology platform enables targeted delivery of radioactive payloads to tumors, enhancing the efficacy of its treatments. Y-mAbs has established strategic partnerships with renowned institutions, such as Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology, to develop and commercialize its licensed products. With a global presence spanning the United States, Western Europe, Eastern Asia, Latin America, and Western Asia, Y-mAbs is poised for growth in the oncology market.

Analyzing the technical data, YMABs stock price is currently at $4.16, below its 20-day and 50-day simple moving averages (SMA) of $4.27 and $4.57, respectively, indicating a downtrend. However, the Average True Range (ATR) of 0.42, equivalent to 10.02% of the current price, suggests significant volatility, presenting potential trading opportunities. Given the stocks 52-week high of $15.69 and low of $3.86, a breakout above the SMA20 or a decline below the 52W Low could be significant.

From a fundamental perspective, Y-mAbs has a market capitalization of $199.67M and a forward P/E ratio of 119.05, indicating high growth expectations. The absence of a trailing P/E ratio is due to the companys negative earnings. Return on Equity (RoE) stands at -32.09%, reflecting the companys investment in research and development. Considering the technical and fundamental data, a forecast for YMAB could be that the stock may experience a short-term bounce if it breaks above the SMA20, potentially targeting the SMA50. However, the long-term trend remains bearish as long as the stock is below the SMA200. Investors should closely monitor the companys clinical trial results, particularly for DANYELZA and GD2-SADA, as these could be catalysts for a potential turnaround.